Another potentially interesting development lies in the combination of PARPi with immune checkpoint inhibition (ICI), based on increased tumor mutational burden (TMB) and upregulation of Programmed Death-Ligand 1 upon PARP inhibition (Peyraud and Italiano 2020). The gene discussed is PARP1; the disease is neoplasm.